224 related articles for article (PubMed ID: 30221071)
21. Efficacy of treatments for mycosis fungoides and Sézary syndrome: nationwide survey responses.
Gettler SL; Fung MA
Dermatol Online J; 2005 Dec; 11(3):6. PubMed ID: 16409902
[TBL] [Abstract][Full Text] [Related]
22. TOX expression and role in CTCL.
McGirt LY; Degesys CA; Johnson VE; Zic JA; Zwerner JP; Eischen CM
J Eur Acad Dermatol Venereol; 2016 Sep; 30(9):1497-502. PubMed ID: 27345620
[TBL] [Abstract][Full Text] [Related]
23. TOX expression in cutaneous T-cell lymphomas: an adjunctive diagnostic marker that is not tumour specific and not restricted to the CD4(+) CD8(-) phenotype.
Schrader AM; Jansen PM; Willemze R
Br J Dermatol; 2016 Aug; 175(2):382-6. PubMed ID: 26931394
[TBL] [Abstract][Full Text] [Related]
24. Ectopic expression of embryonic stem cell and other developmental genes in cutaneous T-cell lymphoma.
Litvinov IV; Netchiporouk E; Cordeiro B; Zargham H; Pehr K; Gilbert M; Zhou Y; Moreau L; Woetmann A; Ødum N; Kupper TS; Sasseville D
Oncoimmunology; 2014 Nov; 3(11):e970025. PubMed ID: 25941598
[TBL] [Abstract][Full Text] [Related]
25. Immune evasion and current immunotherapy strategies in mycosis fungoides (MF) and Sézary syndrome (SS).
Shalabi D; Bistline A; Alpdogan O; Kartan S; Mishra A; Porcu P; Nikbakht N
Chin Clin Oncol; 2019 Feb; 8(1):11. PubMed ID: 30691274
[TBL] [Abstract][Full Text] [Related]
26. Localization of clonal T cells to the epidermis in cutaneous T-cell lymphoma.
Fivenson DP; Hanson CA; Nickoloff BJ
J Am Acad Dermatol; 1994 Nov; 31(5 Pt 1):717-23. PubMed ID: 7929915
[TBL] [Abstract][Full Text] [Related]
27. Serum and cutaneous transcriptional expression levels of IL31 are minimal in cutaneous T cell lymphoma variants.
van Santen S; Out JJ; Zoutman WH; Quint KD; Willemze R; Vermeer MH; Tensen CP
Biochem Biophys Rep; 2021 Jul; 26():101007. PubMed ID: 34027133
[TBL] [Abstract][Full Text] [Related]
28. Presence of
Nedoszytko B; Wierzbicki P; Karenko L; Maciejewska-Radomska A; Stachewicz P; Zabłotna M; Gleń J; Väkevä L; Nowicki RJ; Sokołowska-Wojdyło M
Postepy Dermatol Alergol; 2018 Jun; 35(3):274-279. PubMed ID: 30008645
[TBL] [Abstract][Full Text] [Related]
29. T-cell receptor gamma gene rearrangement by multiplex polymerase chain reaction/heteroduplex analysis in patients with cutaneous T-cell lymphoma (mycosis fungoides/Sézary syndrome) and benign inflammatory disease: correlation with clinical, histological and immunophenotypical findings.
Ponti R; Quaglino P; Novelli M; Fierro MT; Comessatti A; Peroni A; Bonello L; Bernengo MG
Br J Dermatol; 2005 Sep; 153(3):565-73. PubMed ID: 16120144
[TBL] [Abstract][Full Text] [Related]
30. CCR4 in cutaneous T-cell lymphoma: Therapeutic targeting of a pathogenic driver.
Nicolay JP; Albrecht JD; Alberti-Violetti S; Berti E
Eur J Immunol; 2021 Jul; 51(7):1660-1671. PubMed ID: 33811642
[TBL] [Abstract][Full Text] [Related]
31. Expression of Granulysin and FOXP3 in Cutaneous T Cell Lymphoma and Sézary Syndrome.
Shareef MM; Elgarhy LH; Wasfy Rel-S
Asian Pac J Cancer Prev; 2015; 16(13):5359-64. PubMed ID: 26225678
[TBL] [Abstract][Full Text] [Related]
32. Factors Associated With In-Hospital Mortality in Mycosis Fungoides Patients: A Multivariable Analysis.
King ALO; Lee V; Mirza FN; Jairam V; Yang DX; Yu JB; Park HS; Girardi M; Wilson LD; An Y
Cureus; 2022 Aug; 14(8):e28043. PubMed ID: 36120198
[TBL] [Abstract][Full Text] [Related]
33. Analysis of CTCL cell lines reveals important differences between mycosis fungoides/Sézary syndrome
Netchiporouk E; Gantchev J; Tsang M; Thibault P; Watters AK; Hughes JM; Ghazawi FM; Woetmann A; Ødum N; Sasseville D; Litvinov IV
Oncotarget; 2017 Nov; 8(56):95981-95998. PubMed ID: 29221181
[No Abstract] [Full Text] [Related]
34. TOX expression in different subtypes of cutaneous lymphoma.
Morimura S; Sugaya M; Suga H; Miyagaki T; Ohmatsu H; Fujita H; Asano Y; Tada Y; Kadono T; Sato S
Arch Dermatol Res; 2014 Nov; 306(9):843-9. PubMed ID: 25216799
[TBL] [Abstract][Full Text] [Related]
35. Ki67 and CD31 Differential Expression in Cutaneous T-Cell Lymphoma and Its Mimickers: Association with Clinicopathological Criteria and Disease Advancement.
Zohdy M; Abd El Hafez A; Abd Allah MYY; Bessar H; Refat S
Clin Cosmet Investig Dermatol; 2020; 13():431-442. PubMed ID: 32606882
[TBL] [Abstract][Full Text] [Related]
36. Cutaneous T cell lymphoma-mycosis fungoides and Sezary syndrome: an update.
Parker SR; Bethaney JV
G Ital Dermatol Venereol; 2009 Aug; 144(4):467-85. PubMed ID: 19755952
[TBL] [Abstract][Full Text] [Related]
37. Spatially Guided and Single Cell Tools to Map the Microenvironment in Cutaneous T-Cell Lymphoma.
Kalliara E; Belfrage E; Gullberg U; Drott K; Ek S
Cancers (Basel); 2023 Apr; 15(8):. PubMed ID: 37190290
[TBL] [Abstract][Full Text] [Related]
38. The utility of bexarotene in mycosis fungoides and Sézary syndrome.
Panchal MR; Scarisbrick JJ
Onco Targets Ther; 2015; 8():367-73. PubMed ID: 25678803
[TBL] [Abstract][Full Text] [Related]
39. Allogeneic hematopoietic stem cell transplantation in advanced stage mycosis fungoides and Sézary syndrome: a concise review.
Johnson WT; Mukherji R; Kartan S; Nikbakht N; Porcu P; Alpdogan O
Chin Clin Oncol; 2019 Feb; 8(1):12. PubMed ID: 30525754
[TBL] [Abstract][Full Text] [Related]
40. Advanced-stage mycosis fungoides and Sézary syndrome: survival and response to treatment.
Alberti-Violetti S; Talpur R; Schlichte M; Sui D; Duvic M
Clin Lymphoma Myeloma Leuk; 2015 Jun; 15(6):e105-12. PubMed ID: 25817937
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
